Trials / Unknown
UnknownNCT02587910
Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease
Melanole, a Nigella Sativa (Black Seed) Extract for the Treatment of Gastroesophageal Reflux Disease
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- Lebanese American University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Melanole, a Nigella sativa (Black Seed) extract , is studied for the treatment of GERD. Participants, who meet the inclusion criteria, will be divided into two arms. Arm 1: Subjects who meet criteria for GERD will undergo 24 hour pH monitoring. Arm 2: Subjects who meet criteria for GERD and who undergo only symptomatic monitoring of GERD on treatment. All participants will be evaluated before and after the administration of the study product.
Detailed description
Volunteers were recruited in Lebanese American University campuses. Those who fit the inclusion criteria were allowed to choose between two arms: invasive or non-invasive procedures. Volunteers who chose to enroll in the non-invasive arm were given the study product directly after completing the GERD Q questionnaire. A follow-up by phone was done on day 0, 3 , 6 and 11. GERD Q questionnaire was repeated on days 11 and 28 along with a satisfaction rating. Adverse events were reported on a log sheet. Concerning the invasive arm, volunteers were given an appointment at Lebanese American University Medical Center Rizk Hospital to place the 24h pH-metry, after study product was administered. After 7-10 days, the 24h pH monitoring was done again.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Melanole for GERD treatment | Melanole is given orally as 2 capsules TID 5 minutes before each meal |
| DIETARY_SUPPLEMENT | Placebo | Placebo is given orally as 2 capsules TID 5 minutes before each meal |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-04-01
- Completion
- 2016-09-01
- First posted
- 2015-10-27
- Last updated
- 2015-10-28
Locations
2 sites across 1 country: Lebanon
Source: ClinicalTrials.gov record NCT02587910. Inclusion in this directory is not an endorsement.